Polaryx Therapeutics (PLYX) Assets Average (2026)
Polaryx Therapeutics (PLYX) posted quarterly Assets Average of $4.3 million for Q1 2026.
Polaryx Therapeutics (PLYX) Assets Average (2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Assets Average for 1 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average changed N/A year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (changed N/A YoY), while the FY2025 annual figure was $5.1 million, changed N/A from the prior year.
- Assets Average held at $4.3 million in Q1 2026 per PLYX's latest filing.
- Across five years, Assets Average topped out at $4.3 million in Q1 2026 and bottomed at $4.3 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Polaryx Therapeutics | 102.35 Mn | 90.81 Mn | - | 7.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.66 Mn |
| Mar 31, 2026 | 4.34 Mn |